ArticleInfectious agents and cancer2010
HPV - immune response to infection and vaccination.
Article in Infectious agents and cancer, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 97 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
97 citing papers in PubMed, 4 syntheses or guidelines pooled it, 229 citations in OpenAlex.
- Immunotherapy Advances in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Its Relationship With Human Papillomavirus.Frontiers in immunology · 2021Pooled it
- Pooled it
- Medical interventions for high-grade vulval intraepithelial neoplasia.The Cochrane database of systematic reviews · 2015Pooled it
- Interferon gamma +874 T/A polymorphism increases the risk of cervical cancer: evidence from a meta-analysis.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Pooled it
- Risk of venous thromboembolism following human papillomavirus vaccination: a systematic review and meta-analysis.Gynecologic oncology reports · 2026Review
- Cell-Mediated Immunity Against Human Papillomavirus Infection: From Viral Clearance to Oncogenesis.Viruses · 2026Review
- Reduced TLR3 and TLR9 Expression in Epidermodysplasia Verruciformis: Evidence From a Comparative Skin Study.Journal of medical virology · 2025Article
- The most common combination of co-infections genotypic distribution and clearance patterns of high-risk human papillomavirus in Southern China: a population-based retrospective study.Virology journal · 2025Article
- Human Papillomavirus: A Narrative Review for Dental Providers in Prevention and Care.International journal of environmental research and public health · 2025Review
- Human Papillomavirus Vaccine immune responses in an Olive baboon model is not compromised by chronicAIMS microbiology · 2025Article
- Immune responses to human papillomavirus infection and vaccination.Frontiers in immunology · 2025Review
- HPV-specific antibodies in female genital tract secretions captured via first-void urine retain their neutralizing capacity.Human vaccines & immunotherapeutics · 2024Article
- Cervical cancer in Thailand: 2023 update.Obstetrics & gynecology science · 2024Article
- Naturally developed HPV16 antibodies and risk of newly detected cervical HPV infection outcomes.Journal of medical virology · 2024Article
- Strategies to Overcome Hurdles in Cancer Immunotherapy.Biomaterials research · 2024Review
- Role of the epithelium in human papillomavirus and human immunodeficiency virus infections in the female genital tract.Frontiers in reproductive health · 2024Review
- Impact of age at vaccination and cervical HPV infection status on binding and neutralizing antibody titers at 10 years after receiving single or higher doses of quadrivalent HPV vaccine.Human vaccines & immunotherapeutics · 2023Article
- Sex Steroid Modulators and the Development of Buschke-Lowenstein Tumor: A Case Report of an Immunocompetent Patient.Cureus · 2023Article
- Review
- A phase-I, open label clinical trial to assess the safety & tolerability of qHPV vaccine manufactured by Serum Institute of India Pvt. Ltd. in adults.Vaccine: X · 2023Article
37 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
HPV infection in the genital tract is common in young sexually active individuals, the majority of whom clear the infection without overt clinical disease. However most of those who develop benign lesions eventually mount an effective cell mediated immune (CMI) response and the lesions regress.Failure to develop effective CMI to clear or control infection results in persistent infection and, in the case of the oncogenic HPVs, an increased probability of progression to CIN3 and invasive carcinoma. The prolonged duration of infection associated with HPV seems to be associated with effective evasion of innate immunity thus delaying the activation of adaptive immunity.Natural infections in animals show that neutralising antibody to the virus coat protein L1 is protective suggesting that this would be an effective prophylactic vaccine strategy. The current prophylactic HPV VLP vaccines are delivered i.m. circumventing the intra-epithelial immune evasion strategies. These vaccines generate high levels of antibody and both serological and B cell memory as evidenced by persistence of antibody and robust recall responses. However there is no immune correlate - no antibody level that correlates with protection. Recent data on how HPV infects basal epithelial cells and how antibody can prevent this provides a mechanistic explanation for the effectiveness of HPV VLP vaccines.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.